Janux Therapeutics, a clinical-stage biopharmaceutical company, has been upgraded to Strong Buy due to its solid cash position and validated technology platforms. The company discontinued its JANX008 program to focus resources on higher-potential assets, demonstrating financial discipline. Strategic partnerships with Merck and Bristol-Myers Squibb could bring up to $1.8 billion in milestone payments plus royalties, supporting long-term value creation. Despite risks from its early-stage pipeline and potential near-term volatility, Janux's cash runway and platform progress make it a high-risk, long-term investment opportunity.
Warner Bros. Discovery's stock fell 4% following a court decision to pause the $110 billion merger deal between Paramount and Skydance. The judge's intervention raises uncertainty about the future of this major entertainment industry consolidation. I...
Shiba Inu (SHIB) experienced a massive deflation event with its token burn rate increasing by 5,223% in 24 hours, resulting in 401 million tokens permanently removed from circulation. This surge coincided with a nearly 40% price jump and $700 million...
Bitcoin's mining difficulty fell by 0.74% at block 959616, marking the 15th adjustment in 2026 with more cuts than increases. The difficulty drop reflects a 13.82% decline since January, driven mainly by a 26% fall in Bitcoin's price and miners reall...
The XRP community has clarified that Ripple currently holds 32.445 billion XRP in escrow, addressing confusion from outdated figures circulating on social media. This number is verified by the XRP Ledger explorer XRPScan and confirmed by the XRP Ledg...
Flare Networks CEO Hugo Philion announced a six-month plan to transform the XRP decentralized finance ecosystem, XRPFi, by enabling smart contract functionality on the XRP Ledger through Flare's programmable layer. This will allow XRP holders to use ...
